A 20-valent pneumococcal conjugate vaccine prospect had been found to generate reactions across 20 serotypes, fulfilling the main immunogenicity goal of a comprehensive trial that is clinical.
A 20-valent pneumococcal conjugate vaccine prospect had been found to generate reactions across 20 serotypes, fulfilling the main immunogenicity goal of a comprehensive trial that is clinical.